Challenges and pitfalls in the diagnosis of hyperprolactinemia;Desafios e armadilhas no diagnóstico da hiperprolactinemia

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 1, 2014, Pages 9-22

  Vilar, Lucio ^a   Fleseriu, Maria ^b   Bronstein, Marcello D ^c  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diagnostic pitfalls; Hook effect; Hyperprolactinemia; Macroprolactinemia; Pituitary incidentalomas

Indexed keywords

PROLACTIN;

ANAMNESIS; BLOOD; CLASSIFICATION; COMPLICATION; FEMALE; GALACTORRHEA; GEL CHROMATOGRAPHY; HUMAN; HYPERPROLACTINEMIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRECIPITATION; PROLACTINOMA;

CHEMICAL PRECIPITATION; CHROMATOGRAPHY, GEL; FEMALE; GALACTORRHEA; HUMANS; HYPERPROLACTINEMIA; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL HISTORY TAKING; PHYSICAL EXAMINATION; PROLACTIN; PROLACTINOMA;

EID: 84897421437     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000003002     Document Type: Review

References (96)

1. Vilar L, Naves LA, Gadelha MR. Pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metab. 2003;47(4):347-57.
2. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med. 1999;44 (suppl 12):1075-84.
3. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am. 2001;30:585-610.
4. Vilar L, Naves LA. Avaliação diagnóstica da hiperprolactinemia. In: Vilar L, et al, editors. Endocrinologia Clínica. 5a ed. Rio de Janeiro: Guanabara Koogan; 2013. p. 39-49.
5. Bronstein MD. Disorders of prolactin secretion and prolactinomas. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 6th ed. Philadelphia: Saunders/Elsevier; 2010. p. 333-57.
6. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88.
7. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008;37(1):67-99.
8. Josimovich JB, Lavenhar MA, Devanesan MM, Sesta HJ, Wilchins SA, Smith AC. Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril. 1987;47(5):785-91.
9. Thirunavakkarasu K, Dutta P, Sridhar S, Dhaliwal L, Prashad GR, Gainder S, et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013;44(3):750-5.
10. Buvat J, Lemaire A, Buvat-Herbaut M, Fourlinnie JC, Racadot A, Fossati P. Hyperprolactinemia and sexual function in men. Horm Res. 1985;22(3):196-203.
11. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002; 20(4):365-74.
12. La Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007:3(5) 929-51.
13. Suh HK, Frantz AG. Size heterogeneity of human prolactin in plasma and pituitary extracts. J Clin Endocrinol Metab. 1974;39(5):928-35.
14. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev. 1995;16(3):354-69.
15. Jackson RD, Wortsman J, Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab. 1985;61(2):258-64.
16. Kasum M, Oreskovic S, Zec I, Jezek D, Tomic V, Gall V, et al. Macroprolactinemia: new insights in hyperprolactinemia. Biochem Med (Zagreb). 2012;22(2):171-9.
17. Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012;2012:167132.
18. Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J Clin Endocrinol Metab. 1995;80(8):2342-6.
19. Glezer A, Bronstein MD. Approach to the patient with persistent hyperprolactinemia and negative sellar imaging. J Clin Endocrinol Metab. 2012;97(7):2211-6.
20. Glezer A, Soares CR, Vieira JG, Giannella-Neto D, Ribela MT, Goffin V, et al. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab. 2006; 91(3):1048-55.
21. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab. 2005; 90(7):3927-32.
22. Gillam MO, Molitch ME. Prolactin. In: Melmed S, editor. Pituitary. 3rd ed. Philadelphia: Elsevier; 2011. p. 119-66.
23. Tarín JJ, Hermenegildo C, García-Pérez MA, Cano A. Endocrinology and physiology of pseudocyesis. Reprod Biol Endocrinol. 2013;11:39.
24. Voicu V, Medvedovici A, Ranetti AE, Rǎdulescu FŞ. Drug-induced hypoand hyperprolactinemia: mechanisms, clinical and therapeutic consequences. Expert Opin Drug Metab Toxicol. 2013;9(8):955-68.
25. Soares Leaes CG, Pereira-Lima JF, da Costa Oliveira M. A case of sibutramine-induced hyperprolactinemia. Neuro Endocrinol Lett. 2011;32(5):616-8.
26. Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-18.
27. Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R Jr, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008;31(5):436-44.
28. Petit A, Piednoir D, Germain ML, Trenque T. Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database. Therapie. 2003;58(2):159-63.
29. Johnsen E, Kroken RA, Abaza M, Olberg H, Jørgensen HA. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol. 2008;28(6):686-90.
30. Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry. 2011;45(10):830-7.
31. Kunwar AR, Megna JL. Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. Ann Pharmacother. 2003;37(2):206-8.
32. Kamel N, Ilgin SD, Güllü S, Tonyukuk VC, Deda H. Lymphocytic hypophysitis and infundibuloneurohypophysitis; clinical and pathological evaluations. Endocr J. 1999;46(4):505-12.
33. Hekimsoy Z, Kafesçiler S, Güçlü F, Ozmen B. The prevalence of hyperprolactinemia in overt and subclinical hypothyroidism. Endocr J. 2010; 57(12):1011-5.
34. Honbo KS, Herle AJV, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978;64(5):782-7.
35. Stryker TD, Molitch ME. Reversible hyperthyrotropinemia, hyperthyroxinemia and hyperprolactinemia due to adrenal insufficiency. Am J Med.1985;79(2):271-6.
36. Falaschi P, del Pozo E, Rocco A, Toscano V, Petrangeli E, Pompei P, Frajese G. Prolactin release in polycystic ovary. Obstet Gynecol. 1980; 55(5):579-82.
37. Filho RB, Domingues L, Naves L, Ferraz E, Alves A, Casulari LA. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol. 2007; 23(5):267-72.
38. Robin G, Catteau-Jonard S, Young J, Dewailly D. Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality? Gynecol Obstet Fertil. 2011;39(3):141-5.
39. Huang W, Molitch M. Evaluation and management of galactorrhea. Am Fam Physician. 2012;85(11):1073-80.
40. Morgan MY, Jakobovits AW, Gore MB, Wills MR, Sherlock S. Serum prolactin in liver disease and its relationship to gynaecomastia. Gut. 1978;19(3):170-4.
41. Nardoni A, Marchetti E, Geatti O, Di Piazza V, Rossi G, Cedaro P. Prolactin in chronic alcoholic liver diseases with and without gynecomastia. Minerva Med. 1985; 76(1-2):37-42.
42. De Bellis A, Colao A, Pivonello R, Savoia A, Battaglia M, Ruocco G, et al. Antipituitary antibodies in idiopathic hyperprolactinemic patients. Ann NY Acad Sci. 2007; 1107:129-35.
43. Donadio F, Barbieri A, Angioni R, Mantovani G, Beck-Peccoz P, Spada A, Lania AG. Patients with macroprolactinaemia: clinical and radiological features. Eur J Clin Invest. 2007;37(7):552-7.
44. Isik S, Berker D, Tutuncu YA, Ozuguz U, Gokay F, Erden G, et al. Clinical and radiological findings in macroprolactinemia. Endocrine. 2012;41(2):327-33.
45. Suliman AM, Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem. 2003;49(9):1504-9.
46. Modest GA, Fangman JJW. Nipple percing and hyperprolactinemia. N Engl J Med. 2002;347(20):1626-7.
47. Demirtas Y, Sariguney Y, Cukurluoglu O, Ayhan S, Celebi C. Nipple piercing: it is wiser to avoid in patients with hyperprolactinemia. Dermatol Surg. 2004;30(8):1184.
48. Sun GE, Pantalone KM, Gupta M, Kennedy L, Nasr C, Constantiner M, et al. Is chronic nipple piercing associated with hyperprolactinemia? Pituitary. 2013;16(3):351-3.
49. Stanisic TH, Donovan J. Prolactin secreting renal cell carcinoma. J Urol. 1986;136(1):85-6.
50. Hoffman WH, Gala RR, Kovacs K, Subramanian MG. Ectopic prolactin secretion from a gonadoblastoma. Cancer. 1987;60(11):2690-5.
51. Hsu CT, Yu MH, Lee CY, Jong HL, Yeh MY. Ectopic production of prolactin in uterine cervical carcinoma. Gynecol Oncol. 1992;44(2):166-71.
52. Arbaiza D, Noriega K, Marcial J, Wachtel A, Perez C, Torres CF. Ectopic production of prolactin in an infant with non-Hodgkin lymphoma. Med Pediatr Oncol. 1999;32(4):311-2.
53. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, et al. Ectopic production of prolactin by colorectal adenocarcinoma. Dis Colon Rectum. 2001;44(1):119-27.
54. Kallenberg GA, Pesce CM, Norman B, Ratner RE, Silvergerg SG. Ectopic hyperprolactinemia resulting from an ovarian teratoma. JAMA. 1990;263(18):2472-4.
55. Palmer PE, Bogojavlensky S, Bhan AK, Scully RE. Prolactinoma in wall of ovarian dermoid cyst with hyperprolactinemia. Obstet Gynecol. 1990;75(3 Pt 2):540-3.
56. Elms AF, Carlan SJ, Rich AE, Cerezo L. Ovarian tumor-derived ectopic hyperprolactinemia. Pituitary. 2012;15(4):552-5.
57. Proust-Lemoine E, Mitchell V, Deruelle P, Lamblin A, Néraud B, Leroy X, et al. Ectopic hyperprolactinaemia in a woman with a mesocolic perivascular epithelioid cell tumor ("PEComa"). Ann Endocrinol (Paris). 2008;69(3):240-3.
58. Simsir IY, Kocabas GU, Sahin SB, Erdogan M, Cetinkalp S, Saygili F, et al. A case of an ectopic prolactinoma. Gynecol Endocrinol. 2012;28(2):148-9.
59. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002;87(2):581-8.
60. Strachan MW, Teoh WL, Don-Wauchope AC, Seth J, Stoddart M, Beckett GJ. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxf). 2003;59(3):339-46.
61. Vilar L, Moura E, Canadas V, Gusmão A, Campos R, Leal E, et al. Prevalence of macroprolactinemia among 115 patients with hyperprolactinemia. Arq Bras Endocrinol Metab. 2007;51(1):86-91.
62. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab. 2002; 87(12):5410-5.
63. Vieira JG, Tachibana TT, Obara LH, Maciel RM. Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinaemia. Clin Chem. 1988; 44 (8 Pt 1):1758-9.
64. Vieira JGH, Tachibana TT, Ferrer CM, de Sá J, Biscolla RP, Ana Hoff AO, et al. Hyperprolactinemia: new assay more specific for the monomeric form does not eliminate screening for macroprolactin with polyethylene glycol precipitation. Arq Bras Endocrinol Metab. 2010;54(9):856-7.
65. Vilar L, Naves LA, Freitas MC, Lima M, Canadas V, Albuquerque JL, et al. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia. Minerva Endocrinol. 2007;2(2):79-86.
66. Bronstein MD. Editorial: is macroprolactinemia just a diagnostic pitfall? Endocrine. 2012;41(2):169-70.
67. Tamer G, Telci A, Mert M, Uzum AK, Aral F, Tanakol R, et al. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine. 2012;41(1):138-43.
68. Glezer A, D'Alva CB, Salgado LR, Musolino NR, Serafini P, Vieira JG, et al. Pitfalls in pituitary diagnosis: peculiarities of three cases. Clin Endocrinol (Oxf). 2002; 57(1):135-9.
69. Elenkova A, Genov N, Abadzhieva Z, Kirilov G, Vasilev V, Kalinov K, et al. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance. Exp Clin Endocrinol Diabetes. 2013;121(4):201-5.
70. Hayashida SA, Marcondes JA, Soares JM Jr, Rocha MP, Barcellos CR, Kobayashi NK, et al. Evaluation of macroprolactinemia in 259 women under investigation for polycystic ovary syndrome. Clin Endocrinol (Oxf). 2013 Jun 12. [Epub ahead of print]
71. Guay AT, Sabharwal P, Varma S, Malarkey WB. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J Clin Endocrinol Metab. 1996;81(7):2512-4.
72. Vilar L, Czepielewsk MA, Naves LA, Rollin GA, Casulari LA, Coelho CE. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract. 2007;13(4):396-402.
73. Teoh SK, Lex BW, Mendelson JH, Mello NK, Cochin J. Hyperprolactinemia and macrocytosis in women with alcohol and polysubstance dependence. J Stud Alcohol. 1992;53(2):176-82.
74. Freitas MC, Lima LHC. Diagnóstico e tratamento do hipotiroidismo. In: Vilar L, et al., eds. Endocrinologia Clínica. 5a ed. Rio de Janeiro: Guanabara Koogan, 2013. p. 297-309.
75. Vance ML, Thorner M. Prolactinoma. Endocrinol Metab Clin North Am. 1987;16:731-54.
76. Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977;296(11):589-600.
77. Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am. 1999;28:81-117.
78. Glezer A, Paraiba DB, Bronstein MD. Rare sellar lesions. Endocrinol Metab Clin North Am. 2008;37:195-211.
79. Naidich MJ, Russell EJ. Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am. 1999;28:45-79.
80. Molitch ME. Management of incidentally found nonfunctional pituitary tumors. Neurosurg Clin N Am. 2012;23(4):543-53.
81. Vilar L, Azevedo MF, Barisic G, Naves LA. Pituitary incidentalomas. Arq Bras Endocrinol Metabol. 2005;49(5):651-6.
82. Abram M, Brue T, Morange I, Girard N, Guibout M, Jaquet P. Pituitary tumor syndrome and hyperprolactinemia in peripheral hypothyroidism. Ann Endocrinol (Paris). 1992;53(5/6):215-23.
83. Atchison JA, Lee PA, Albright AL. Reversible suprasellar pituitary mass secondary to hypothyroidism. JAMA. 1989;262(22):3175-7.
84. Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf). 2006;65(4):524-9.
85. Korevaar T, Wass JA, Grossman AB, Karavitaki N. Disconnection hyperprolactinaemia in nonadenomatous sellar/parasellar lesions practically never exceeds 2000 mU/l. Clin Endocrinol (Oxf). 2012;76(4):602-3.
86. Albuquerque FC, Hinton DR, Weiss MH. Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma. J Neurosurg. 1998;89(6):1043-6.
87. Smith MV, Laws Jr ER. Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels. Neurosurgery. 1994;34(5):834-9.
88. Duarte FH, Machado MC, Lima JR, Salgado LR. Severe hyperprolactinemia associated with internal carotid artery aneurysm: differential diagnosis between prolactinoma and hypothalamic-pituitary disconnection. Arq Bras Endocrinol Metabol. 2008;52(7):1189-93.
89. Fleseriu M, Lee M, Pineyro MM, Skugor M, Reddy SK, Siraj ES, et al. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'. J Neurooncol. 2006;79(1):41-3.
90. Frieze TW, Mong DP, Koops MK. "Hook effect" in prolactinomas: case report and review of literature. Endocr Pract. 2002;8(4):296-303.
91. Bahuleyan B, Menon G, Nair S, Rao BR, Easwer HV, Krishna K. Non-surgical management of cystic prolactinomas. J Clin Neurosci. 2009;16(11):1421-4.
92. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6(4):245-9.
93. Notsu K, Ito Y, Furuya H, Ohguni S, Kato Y. Incidence of hyperprolactinemia in patients with Hashimoto's thyroiditis. Endocr J. 1997;44(1):89-94.
94. Jamaluddin FA, Sthaneshwar P, Hussein Z, Othman N, Chan SP. Importance of screening for macroprolactin in all hyperprolactinaemic sera. Malays J Pathol. 2013;35(1):59-63.
95. McKenna TJ. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf). 2009;71(4):466-9.
96. Lu CC, Hsieh CJ. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients. Kaohsiung J Med Sci. 2012;28(2):94-9.